Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 11/20 | 0.47 |
| ▸ | KDR | P35968 | 11/20 | 0.47 |
| ▸ | KIF5B | P33176 | 8/20 | 0.47 |
| ▸ | EGFR | P00533 | 8/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | FBP1 | P09467 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL535332 | 0.82 | RET (0.48) | RETKDRKIF5BEGFRABCG2 | |
| SCHEMBL13310109 | 0.80 | EGFR (0.53) | RETKDRKIF5BEGFRABCG2 | |
| SCHEMBL13310095 | 0.80 | HDAC3 (0.48) | RETKDRKIF5BEGFR | |
| SCHEMBL13438440 | 0.76 | EGFR (0.52) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL13485446 | 0.75 | KDR (0.50) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL5241456 | 0.73 | KDR (0.83) | RETKDRKIF5BEGFRABCG2 | |
| SCHEMBL13404551 | 0.73 | EGFR (0.49) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL535258 | 0.72 | EGFR (0.52) | RETKDRKIF5BEGFRABCG2 | |
| SCHEMBL535885 | 0.71 | EGFR (0.51) | RETKDRKIF5BEGFRSRC | |
| SCHEMBL13404542 | 0.71 | EGFR (0.56) | RETKDRKIF5BEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-19 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-09 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688691-B2 | Macrocyclic quinazole derivatives and their use as MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | JANSSEN-CILAG (FR) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256714-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | RET 1558/4885KDR 2610/4885KIF5B 3765/4885 |
| US-20100152174-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR1I2, NR3C2 | RET 1211/4885KDR 2757/4885KIF5B 3696/4885 |
| US-20170320894-A1 | MACROCYCLIC QUINAZOLE DERIVATIVES AND THEIR USE AS MTKI | NR1I3, NR3C2, NR1I2 | RET 1558/4885KDR 2610/4885KIF5B 3765/4885 |
| US-10208062-B2 | Macrocyclic quinazole derivatives and their use as MTKI | NR1I3, NR3C2, NR1I2 | RET 1558/4885KDR 2610/4885KIF5B 3765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.